【美股财报】Disc Medicine Inc 2024年度报告.pdf

3D MEDICINES-B二零二二年年报

Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines

Annex 1 Socio-Economic Analysis Of the potential restriction of the perand polyfluoroalkyl substances (PFAS) used in the production, packaging and delivery of human medicinal products

Blueprint Medicines Corp 2024年度报告

Disc Medicine Inc美股招股说明书(2025-01-23版)

Disc Medicine Inc美股招股说明书(2025-01-21版)

How Off-Label Use of Medicines Drives Health-Care Use and Disability

Report of the second joint meeting (hybrid) of the WHO Global Advisory Committee on Vaccine Safety and the WHO Advisory Committee on Safety of Medicinal Products, 14–16 December2022

3D MEDICINES二零二三年年报

3D MEDICINES二零二三年中期报告